Histotripsy Dose Impacts Treated Tumor Immune Infiltration and Survival Outcomes in a Murine B16F10 Melanoma Model
Cancers · 26.11.2025 · 17 (23) · 3773
DOI: 10.3390/cancers17233773 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 26.11.2025. Verfasst von Reliza McGinnis und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIBIB NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Background/Objectives: Preclinical animal studies and clinical case reports have shown evidence of histotripsy being capable of inducing anti-tumor immune responses strong enough to inhibit tumor growth of off-target tumors. Previous studies exploring histotripsy immune stimulation have used a single therapy dose. This study aims to explore how histotripsy dose affects local tumor immune stimulation in a murine melanoma model.
Methods
C57BL/6J mice bearing subcutaneous B16F10 tumors were treated with histotripsy using an ultrasound-guided 8-element 1 MHz transducer operating at a 100 Hz pulse repetition frequency (PRF) and >30 MPa peak-negative pressure. The histotripsy dose was defined by the number of pulses (8, 20, 40, or 100) per focal location (ppl). Tissue damage and residual tissue structure were measured histologically and scored by a trained pathologist. The longitudinal effect of histotripsy dosing was assessed using tumor growth and survival. Acute immune stimulation was measured at days 2 and 7 post-treatment via immunofluorescence staining of the treated tumor.
Results
Histotripsy doses at 20, 40, and 100 ppl achieved significant tumor necrosis within the target region (>75%), with residual structure decreasing as the dose increased. Overall, the greatest tumor control was observed in mice that received the 40 ppl dose compared to untreated mice. This correlates with the 40 ppl dose also having the largest increase in CD45+ immune cells and CD8+ T cells 7 days post-treatment compared to untreated mice.
Conclusions
The effect of histotripsy dosing on immune infiltration and tumor growth highlights the significant impact of histotripsy dose on clinical effects.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
- Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA.
- Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
- Department of Cell Biology, Van Andel Institute, Grand Rapids, MI 49503, USA.
- Department of Radiology, University of Michigan, Ann Arbor, MI 48109, USA.
- Department of Neurosurgery, University of Michigan, Ann Arbor, MI 48109, USA.
ORCID-Profile: Reliza McGinnis, Hanna Kim, Jiaqi Shi, Lili Zhao, Clifford S Cho, Zhen Xu
Förderung
- NIH HHS
- NIBIB NIH HHS
- NCI NIH HHS
- National Institute of Health
Zitieren
APA
McGinnis, R., Song, B., Kim, H., Lorenzon, A., Shi, J., Zhao, L., Cho, C. S., Ganguly, A., & Xu, Z. (2025). Histotripsy Dose Impacts Treated Tumor Immune Infiltration and Survival Outcomes in a Murine B16F10 Melanoma Model. Cancers, 17(23), 3773. https://doi.org/10.3390/cancers17233773
Vancouver
McGinnis R, Song B, Kim H, Lorenzon A, Shi J, Zhao L, et al. Histotripsy Dose Impacts Treated Tumor Immune Infiltration and Survival Outcomes in a Murine B16F10 Melanoma Model. Cancers. 2025;17(23):3773. doi:10.3390/cancers17233773
BibTeX
@article{McGinnis2025,
author = {McGinnis, Reliza and Song, Brian and Kim, Hanna and Lorenzon, Anna and Shi, Jiaqi and Zhao, Lili and Cho, Clifford S and Ganguly, Anutosh and Xu, Zhen},
title = {Histotripsy Dose Impacts Treated Tumor Immune Infiltration and Survival Outcomes in a Murine B16F10 Melanoma Model},
journal = {Cancers},
year = {2025},
volume = {17},
number = {23},
pages = {3773},
doi = {10.3390/cancers17233773}
}
EUVIMED